Search Results for: BSX
A large drop in the sale of drug coated stents knocked Boston Scientific’s (BSX) quarter way down. The company’s second-quarter profit, excluding charges, was $271 million, or 18 cents...
Published:
The list of management screw-ups at Boston Scientific (BSX) is almost too long to number. It bought rival Guidant and added $7 billion in debt in the process. Some of Guidant’s products were not as...
Published:
Last Updated:
Today after the close, SEC Filings have shown that Boston Scientific Corp. (NYSE: BSX) co-founders have been forced to sell more common stock to meet margin calls. Unfortunately this isn’t the...
Published:
Last Updated:
Workers in industries that are not doing well usually get laid off. But, it is not a good omen when workers in robust sectors of the economy are losing their jobs. Countrywide (CFC) has said that...
Published:
Boston Scientific (NYSE:BSX), the worst run of the large medical device and pharma firms based in the US, announced an operating loss for the fourth quarter of 2009 of $1.23 billion. The company’s...
Published:
On Tuesday morning, we’ll get to see earnings out of Boston Scientific Corp. (NYSE:BSX). The estimates from First Call for the medical device developer are $0.09 EPS on $2.13 billion in...
Published:
Last Updated:
Boston Scientific (BSX) had planned to take its fast-growing endosurgery group public to raise as much as $1 billion. According to The Associated Press: "The endosurgery unit has recently...
Published:
After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that "patients given drug-coated stents after an acute heart attack are nearly five...
Published:
The government is fond of using taxes and tax benefits to change behavior. Put a big tax on cigarettes and people will smoke less. Put a "gas guzzler" tax on big cars and people will drive...
Published:
Boston Scientific Corporation (NYSE: BSX) is making a move which may be a questionable one if you have followed this stock for a while. The company said that President and CEO Jim Tobin will be...
Published:
Last Updated:
Boston Scientific Corporation (NYSE: BSX) is already losing its replacement CEO. Ray Elliott has announced that he will retire as President and Chief Executive Officer on December 31, 2011. As...
Published:
Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to emerge that the products could cause heart problems. There have been several...
Published:
Boston Scientific Corporation (NYSE: BSX) is finally getting free from President and Chief Executive Officer Jim Tobin. This was one our top 10 CEO’s to go for 2009 as his tenure has been bad. ...
Published:
Last Updated:
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its...
Published:
Boston Scientific’s (BSX) problem with its huge drug-coated stent business have become so severe that the company is looking at selling some of its assets. The stent have been blamed for...
Published: